Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, Thomas, Chase, Andrew J, Score, Joannah, Hidalgo-Curtis, Claire E, Bryant, Catherine, Jones, Amy V, Waghorn, Katherine, Zoi, Katerina +10 more·2010·Nature Genetics

DOI 10.1038/ng.621

Cited by (1,000)

Items 101–200 of 1,000

Targeting EZH2 in cancer therapy
Makoto Yamagishi, Kaoru Uchimaru · 2017 · Current Opinion in Oncology
Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability
Katrina Tatton‐Brown, Chey Loveday, Shawn E. Yost, Matthew Clarke, Emma Ramsay, Anna Zachariou, Anna Elliott, Harriet Wylie, Anna Ardissone, Olaf Rittinger et al. · 2017 · The American Journal of Human Genetics
The interplay between DNA and histone methylation: molecular mechanisms and disease implications
Li, Yinglu, Chen, Xiao, Lu, Chao · 2021 · The EMBO Reports
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
Frédérik Damm, Virginie Chesnais, Yasunobu Nagata, Kenichi Yoshida, Laurianne Scourzic, Yusuke Okuno, Raphaël Itzykson, Masashi Sanada, Yuichi Shiraishi, Véronique Gelsi‐Boyer et al. · 2013 · Blood
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang, Raajit K. Rampal, Taghi Manshouri, Jay L. Patel, Nana Yaa Mensah, Andrew Kayserian, Todd Hricik, Adriana Heguy, Cyrus V. Hedvat, Mithat Gönen et al. · 2012 · Blood
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintás‐Cardama, Omar Ibrahim Abdel-Wahab, Taghi Manshouri, Outi Kilpivaara, Jörge E. Cortes, Anne-Laure Roupie, Su-Jiang Zhang, David Harris, Zeev E. Estrov, Hagop M. Kantarjian et al. · 2013 · Blood
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
Anne Laugesen, Jonas Westergaard Højfeldt, Kristian Helin · 2016 · Cold Spring Harbor Perspectives in Medicine
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
Susanne Schnittger, Christiane Eder, Sabine Jeromin, Tamara Alpermann, Annette Fasan, Vera Grossmann, Alexander Kohlmann, Thomas Illig, N. Klopp, H.‐Erich Wichmann et al. · 2012 · Leukemia
Zebrafish Models of Cancer—New Insights on Modeling Human Cancer in a Non-Mammalian Vertebrate
Martina Hason, Petr Bartůněk · 2019 · Genes
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola, Róbert Královics · 2014 · Blood
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael Robert Savona, Luca Malcovati, Rami S. Komrokji, Ramon Velasquez Tiu, Tariq I. Mughal, Attilio Orazi, Jean‐Jacques Kiladjian, Eric Padron, Éric Solary, Raoul Tibes et al. · 2015 · Blood
MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines
Minoru Terashima, Shoichiro Tange, Akihiko Ishimura, Takeshi Suzuki · 2016 · Journal of Biological Chemistry
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells
Susumu Goyama, Janet Schibler, Lea Cunningham, Yue Zhang, Yalan Rao, Nahoko Nishimoto, Masahiro Marshall Nakagawa, André Olsson, Mark Wunderlich, Kevin A. Link et al. · 2013 · Journal of Clinical Investigation
Targeting histone lysine methylation in cancer
John P. McGrath, Patrick Trojer · 2015 · Pharmacology & Therapeutics
Driver mutations of cancer epigenomes
David M. Roy, Logan A. Walsh, Timothy An-thy Chan · 2014 · Protein & Cell
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
Satomi Tanaka, S. Miyagi, G. Sashida, T. Chiba, Jin Yuan, M. Mochizuki-Kashio, Yutaka Suzuki, S. Sugano, C. Nakaseko, K. Yokote et al. · 2012 · Blood
<i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
Gaidzik, Verena I., Paschka, Peter, Späth, Daniela, Habdank, Marianne, Köhne, Claus-Henning, Germing, Ulrich, von Lilienfeld-Toal, Marie, Held, Gerhard, Horst, Heinz-August, Haase, Detlef et al. · 2012 · Journal of Clinical Oncology
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions
Samuel Quentin, Wendy Cuccuini, Raphaël Ceccaldi, Olivier Nibourel, Corinne Pondarré, Marie‐Pierre Pagès, Nadia Vasquez, Catherine Dubois d’Enghien, Jérôme Larghero, Régis Peffault de Latour et al. · 2011 · Blood
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Thorsten Klampfl, Ashot S. Harutyunyan, Tiina Berg, Bettina Gisslinger, Martin Schalling, Klaudia Bagienski, Damla Olcaydu, Francesco Passamonti, Elisa Rumi, Daniela Pietra et al. · 2011 · Blood
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Candace J. Poole, Jan van Riggelen · 2017 · Genes
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Score, Joannah, Hidalgo-Curtis, Claire, Jones, Amy V., Winkelmann, Nils, Skinner, Alison, Ward, Daniel, Zoi, Katerina, Ernst, Thomas, Stegelmann, Frank, Döhner, Konstanze et al. · 2012 · Blood
EZH2 in normal and malignant hematopoiesis
Kirstin Lund, Peter D. Adams, Mhairi Copland · 2013 · Leukemia
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
Tomoya Muto, Goro Sashida, Motohiko Oshima, George Russel Wendt, Makiko Mochizuki‐Kashio, Yasunobu Nagata, Masashi Sanada, Satoru Miyagi, Atsunori Saraya, Asuka Kamio et al. · 2013 · The Journal of Experimental Medicine
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia
Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Aiko Sato‐Otsubo, Keisuke Kataoka, Yusuke Sato, Yosaku Watatani, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida et al. · 2018 · Nature Communications
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Zhimin, Liu, Yuxuan, Cai, Feng, Patrick, McKenzie, Zmajkovic, Jakub, Cao, Hui, Zhang, Yuannyu, Tasdogan, Alpaslan, Chen, Mingyi, Qi, Le et al. · 2019 · Cancer Discovery
Recent developments in myelodysplastic syndromes
Rafael L. Bejar, David P. Steensma · 2014 · Blood
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
Kristen M. Meldi, Tingting Qin, Francesca Buchi, Nathalie M Droin, Jason R. Sotzen, Jean‐Baptiste Micol, Dorothée Selimoglu‐Buet, Erico Masala, Bernardino Allione, Daniela Maria Gioia et al. · 2015 · Journal of Clinical Investigation
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
Renée Beekman, Marijke G. Valkhof, Mathijs Arnoud Sanders, Paulette van Strien, Jurgen R. Haanstra, L Broeders, W. M. C. Geertsma-Kleinekoort, Anjo J.P. Veerman, Peter J.M. Valk, Roel G.W. Verhaak et al. · 2012 · Blood
The Epigenetic Hallmarks of Cancer
Manel Esteller, Mark A. Dawson, Cigall Kadoch, Feyruz Virgilia Rassool, Peter A. Jones, Stephen B. Baylin · 2024 · Cancer Discovery
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
Rocquain, Julien, Carbuccia, Nadine, Trouplin, Virginie, Raynaud, Stéphane, Murati, Anne, Nezri, Meyer, Tadrist, Zoulika, Olschwang, Sylviane, Vey, Norbert, Birnbaum, Daniel et al. · 2010 · BMC Cancer
Histone Modifiers in Cancer: Friends or Foes?
Idan Cohen, Elżbieta Poręba, Kinga Kamieniarz-Gdula, Robert Schneider · 2011 · Genes & Cancer
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells
Kotini, Andriana G, Chang, Chan-Jung, Boussaad, Ibrahim, Delrow, Jeffrey J, Dolezal, Emily K, Nagulapally, Abhinav B, Perna, Fabiana, Fishbein, Gregory A, Klimek, Virginia M, Hawkins, R David et al. · 2015 · Nature Biotechnology
DNMT3A mutations in myeloproliferative neoplasms
Frank Stegelmann, Lars Bullinger, Richard F. Schlenk, Peter Paschka, Martin Grießhammer, Carmen Blersch, Susanne Antje Kuhn, Stefanie Schauer, Hartmut Döhner, Konstanze Döhner · 2011 · Leukemia
Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation
G. Sashida, H. Harada, H. Matsui, M. Oshima, Makiko Yui, Y. Harada, Satomi Tanaka, M. Mochizuki-Kashio, Chang-Shan Wang, A. Saraya et al. · 2014 · Nature Communications
Epigenetics of hematopoiesis and hematological malignancies
Deqing Hu, Ali Shilatifard · 2016 · Genes & Development
The JAK2 exon 12 mutations: A comprehensive review
Linda M. Scott · 2011 · American Journal of Hematology
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan, Siok‐Bian Ng, Jim Liang-Seah Tay, Baohong Lin, Tze Loong Koh, Joy Mei-Ling Tan, Viknesvaran Selvarajan, Shaw-Cheng Liu, Chonglei Bi, Shi Wang et al. · 2013 · Blood
Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height
Katrina Tatton‐Brown, Sandra Hanks, Elise Ruark, Anna Zachariou, Silvana Del Vecchio Duarte, Emma Ramsay, Katie M.G. Snape, Anne Murray, Elizabeth R Perdeaux, Sheila Seal et al. · 2011 · Oncotarget
Gene regulation of mammalian long non-coding RNA
Heeyoun Bunch · 2017 · Molecular Genetics and Genomics
Epigenetic cancer therapy: rationales, targets and drugs
Rius, M, Lyko, F · 2012 · Oncogene
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
Mandy Brecqueville, Jérôme Rey, François Bertucci, Emilie Coppin, Pascal Finetti, Nadine Carbuccia, Nathalie Cervera, Véronique Gelsi‐Boyer, Christine Arnoulet, Olivier Gisserot et al. · 2012 · Genes Chromosomes and Cancer
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Irfan Ahmed Asangani, Bushra Ateeq, Qi Cao, Lois M. Dodson, Mithil B. Pandhi, Lakshmi Priya Kunju, Rohit Mehra, Robert J. Lonigro, Javed Siddiqui, Nallasivam Palanisamy et al. · 2012 · Molecular Cell
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution
Shang‐Ju Wu, Yuan‐Yeh Kuo, Hsin‐An Hou, Li-Yu Li, Mei‐Hsuan Tseng, Chi‐Fei Huang, Fen‐Yu Lee, Ming-Chih Liu, Chia‐Wen Liu, Chien‐Ting Lin et al. · 2012 · Blood
The role of cytokines in the initiation and progression of myelofibrosis
Hans Carl Hasselbalch · 2013 · Cytokine & Growth Factor Reviews
Myeloid malignancies: mutations, models and management
Anne Murati, Mandy Brecqueville, Raynier Devillier, Julien Mozziconacci, Véronique Gelsi‐Boyer, Daniel Birnbaum · 2012 · BMC Cancer
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
Omar Ibrahim Abdel-Wahab, Animesh Dev Pardanani, Raajit K. Rampal, Terra L. Lasho, Ross L. Levine, Ayalew Tefferi · 2011 · Leukemia
Developmental Control of Polycomb Subunit Composition by GATA Factors Mediates a Switch to Non-Canonical Functions
Jian Xu, Zhen Shao, Dan Li, Huafeng Xie, Woojin Kim, Jialiang Huang, Jordan E. Taylor, Luca Pinello, Kimberly Glass, Jacob D. Jaffe et al. · 2015 · Molecular Cell
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Lorenzo Tozzi, Flavia Biamonte, Niccolò Bartalucci, Elisabetta Gattoni, Letizia Lupo et al. · 2011 · Blood
Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype
Katrina Tatton‐Brown, Anne Murray, Sandra Hanks, Jenny B. Douglas, Ruth Armstrong, Siddharth Banka, Lynne M. Bird, Carol L. Clericuzio, Valérie Cormier‐Daire, Tom Cushing et al. · 2013 · American Journal of Medical Genetics Part A
Identification of Somatic Mutations in Parathyroid Tumors Using Whole-Exome Sequencing
M. Kyle Cromer, Lee F. Starker, Murim Choi, Robert Udelsman, Carol J. Nelson-Williams, Richard P. Lifton, Tobias Carling · 2012 · The Journal of Clinical Endocrinology & Metabolism
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Gerard L. Brien, Daria G. Valerio, Scott A. Armstrong · 2016 · Cancer Cell
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Mary T. Scott, Koorosh Korfi, Peter Saffrey, Lisa E. M. Hopcroft, Ross Kinstrie, Francesca Pellicano, Carla Guenther, Paolo Gallipoli, Michelle Maria Araujo Cruz, Karen M. Dunn et al. · 2016 · Cancer Discovery
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
Daisuke Honma, Osamu Kanno, Jun Watanabe, Junzo Kinoshita, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi et al. · 2017 · Cancer Science
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Malik Bisserier, Narendra Wajapeyee · 2018 · Blood
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
Vera Großmann, Alexander Kohlmann, Christiane Eder, Claudia Haferlach, Wolfgang Kern, Nicholas C.P. Cross, Torsten Haferlach, Susanne Schnittger · 2011 · Leukemia
EZH2 Y641 mutations in follicular lymphoma
Csaba Bödör, Ciarán Ó’Riain, David Wrench, J. Matthews, Sunil Iyengar, Hira Tayyib, Maria Calaminici, Andrew James Clear, Sameena Iqbal, Hilmar Quentmeier et al. · 2011 · Leukemia
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
M Schmidt, Jenny Rinke, Vivien Schäfer, Susanne Schnittger, Alexander Kohlmann, Ellen Obstfelder, Christa Kunert, J Ziermann, Nils Winkelmann, Ekkehard Eigendorff et al. · 2014 · Leukemia
Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations
Hong Wu, Hong Zeng, Aiping Dong, Fengling Li, Hao He, Guillermo A. Senisterra, Alma Seitova, Shili Duan, Peter J. Brown, Masoud Vedadi et al. · 2013 · PLoS ONE
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Azra Raza, Naomi Galili · 2012 · Nature reviews. Cancer
Methylation across the central dogma in health and diseases: new therapeutic strategies
Ruochen Liu, Erhu Zhao, Huijuan Yu, Chaoyu Yuan, Muhammad Nadeem Abbas, Hongjuan Cui · 2023 · Signal Transduction and Targeted Therapy
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Rodrigo Almeida Toledo, Yuejuan Qin, Zi-Ming Cheng, Qing Gao, Shintaro Iwata, Gustavo M. Silva, Manju Lata Prasad, Idris Tolgay Ocal, Sarika N. Rao, Neil Aronin M. D et al. · 2015 · Clinical Cancer Research
Diverse involvement of EZH2 in cancer epigenetics.
Pamela Völkel, Barbara Dupret, Xuefen Le Bourhis, Pierre‐Olivier Angrand · 2015 · PubMed Central
Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner
Makiko Mochizuki‐Kashio, Kazumasa Aoyama, Goro Sashida, Motohiko Oshima, Takahisa Tomioka, Tomoya Muto, Changshan Wang, Atsushi Iwama · 2015 · Blood
Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
Daniel P. Mould, Alison E. McGonagle, Daniel H. Wiseman, Emma L. Williams, Allan Michael Jordan · 2014 · Medicinal Research Reviews
Age-related mutations and chronic myelomonocytic leukemia
Clinton C. Mason, Jamshid Sorouri Khorashad, Srinivas Kiran Tantravahi, Todd W. Kelley, Matthew S. Zabriskie, Dongqing Yan, Anthony D. Pomicter, Kamika R. Reynolds, Anna M. Eiring, Zev N. Kronenberg et al. · 2015 · Leukemia
Engaging chromatin: PRC2 structure meets function
Paul Chammas, Ivano Mocavini, Luciano Di Croce · 2019 · British Journal of Cancer
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Ailin Zhao, Hui Zhou, Jinrong Yang, Meng Li, Ting Niu · 2023 · Signal Transduction and Targeted Therapy
Single-molecule decoding of combinatorially modified nucleosomes
Efrat Shema, Daniel R. Jones, Noam Shoresh F, Laura Donohue, Oren Ram, B Bernstein · 2016 · Science
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma
Junli Yan, Boheng Li, Baohong Lin, Pei Tsung Lee, Tae‐Hoon Chung, Joy Mei-Ling Tan, Chonglei Bi, Xue Ting Lee, Viknesvaran Selvarajan, Siok‐Bian Ng et al. · 2016 · Blood
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
Shahper N. Khan, Anna Maria Jankowska, Reda Z. Mahfouz, Andrew Jeffrey Dunbar, Yuka Sugimoto, Naoko Hosono, Zhenbo Hu, Venugopalan Cheriyath, Sergei Vatolin, Bartlomiej P. Przychodzen et al. · 2013 · Leukemia
Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer
Joana Carvalho, Nicole C.T. van Grieken, Patrícia M. Pereira, Sónia Sousa, Marianne Tijssen, Tineke E. Buffart, Begoña Diosdado, Heike Irmgard Grabsch, Manuel A. S. Santos, Gerrit A. Meijer et al. · 2012 · The Journal of Pathology
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
Maximilian Mossner, Johann-Christoph Jann, Janina Wittig, Florian Nolte, Stéphanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Iris Palme, Christina Xanthopoulos et al. · 2016 · Blood
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
Animesh Dev Pardanani, Alessandro Maria Vannucchi, Francesco Passamonti, Francisco Cervantes, Tiziano Barbui, Ayalew Tefferi · 2010 · Leukemia
How I treat myelofibrosis
Ayalew Tefferi · 2011 · Blood
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Faisal Basheer, George Giotopoulos, Eshwar Meduri, Haiyang Yun, Milena M. Mazan, Daniel Sasca, Paolo Gallipoli, Ludovica Marando, Malgorzata Gozdecka, Ryan Asby et al. · 2019 · The Journal of Experimental Medicine
Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Brandon R. Lowe, Lily Maxham, Joshua J. Hamey, Marc Ronald Wilkins, Janet F. Partridge · 2019 · Cancers
Loss of Ezh2 synergizes with JAK2 -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
Takafumi Shimizu, Lucia Kubovčáková, Ronny Nienhold, Jakub Zmajkovic, Sara C. Meyer, Hui Hao-Shen, Florian M. Geier, Stephan Dirnhofer, Paola Guglielmelli, Alessandro Maria Vannucchi et al. · 2016 · The Journal of Experimental Medicine
Targeting EZH2 and PRC2 dependence as novel anticancer therapy
Bowen Xu, Kyle D. Konze, Jian Jun Jin, Gang Greg Wang · 2015 · Experimental Hematology
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Sebastian Vosberg, Philipp A. Greif · 2019 · Genes Chromosomes and Cancer
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis
Andrés Jerez, Yuka Sugimoto, Hideki Makishima, Amit K. Verma, Anna Maria Jankowska, Bartlomiej P. Przychodzen, Valeria Visconte, Ramon Velasquez Tiu, Christine L. O’Keefe, Azim M. Mohamedali et al. · 2012 · Blood
H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo
André Bortolini Silveira, Lawryn H. Kasper, Yiping Fan, Hongjian Jin, Gang Wu, Timothy I. Shaw, Xiaoyan Zhu, Jon D. Larson, John B. Easton, Ying Shao et al. · 2019 · Acta Neuropathologica
Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma
Min Hua Zheng, Yaping Jiang, Wei Chen, Kaide Li, Xin Liu, Shiyu Gao, Hao Feng, Shasha Wang, Jian Dong Jiang, Xiangrui Ma et al. · 2015 · Oncotarget
EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
Russell J.H. Ryan, Mai Nitta, Darrell R. Borger, Lawrence R. Zukerberg, Judith A. Ferry, Nancy L. Harris, Anthony John Iafrate, B Bernstein, Aliyah R. Sohani, Long P. Le · 2011 · PLoS ONE
Clonal evolution of acute leukemia genomes
Max Jan, Ravindra Majeti · 2012 · Oncogene
PRPF8 defects cause missplicing in myeloid malignancies
Amina Kurtović-Kozarić, Bartlomiej P. Przychodzen, Jagjit Singh, Maria M. Konarska, Michael J. Clemente, Zaher K. Otrock, Megan O. Nakashima, Eric D. Hsi, Kenichi Yoshida, Yuichi Shiraishi et al. · 2014 · Leukemia
CHD5 Is Required for Neurogenesis and Has a Dual Role in Facilitating Gene Expression and Polycomb Gene Repression
Chris M. Egan, Ulrika Nyman, Julie Skotte, Gundula Streubel, Siobhán A. Turner, David J O’Connell, Vilma Rraklli, Michael-John Dolan, Naomi Chadderton, Klaus H. Hansen et al. · 2013 · Developmental Cell
Histone Methyltransferase EZH2 Is Transcriptionally Induced by Estradiol as Well as Estrogenic Endocrine Disruptors Bisphenol-A and Diethylstilbestrol
Arunoday Bhan, Imran Hussain, Khairul I. Ansari, Samara A.M. Bobzean, Linda I. Perrotti, Subhrangsu S. Mandal · 2014 · Journal of Molecular Biology
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Ni Li, Wei Xue, Huairui Yuan, Baijun Dong, Yufeng Ding, Yongfeng Liu, Min Jiang, Shan Kan, Tongyu Sun, Jiale Ren et al. · 2017 · Journal of Clinical Investigation
A complex Polycomb issue: the two faces of EZH2 in cancer
Hanno R. Hock · 2012 · Genes & Development
Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
Nicholas C.P. Cross · 2011 · Hematology
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Raphaël Itzykson, Pierre Fenaux, David Bowen, Nicholas C.P. Cross, Jörge E. Cortes, Théo de Witte, Ulrich Germing, Francesco Onida, Eric Padron, Uwe Platzbecker et al. · 2018 · HemaSphere
The molecular pathogenesis of the myelodysplastic syndromes
Andrea Pellagatti, Jacqueline Boultwood · 2015 · European Journal Of Haematology
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Relja Popovic, Jonathan D. Licht · 2012 · Cancer Discovery
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia
Jun-Wei Shi, Eric Wang, Johannes Zuber, Amy R. Rappaport, Meredith J. Taylor, Christopher Johns, S. W. Lowe, Christopher R. Vakoc · 2012 · Oncogene
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
Sylvie Hermouet, Edith Bigot‐Corbel, Betty Gardie · 2015 · Mediators of Inflammation
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
Bayley A. Jones, Sooryanarayana Varambally, Rebecca Christian Arend · 2018 · Molecular Cancer Therapeutics
Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer
Ke Chen, Haibing Xiao, Jin Zeng, Yu Gan, Hui Zhou, Chunhua Huang, Weimin Yao, Wei Xiao, Junhui Hu, Wei Guan et al. · 2016 · Clinical Cancer Research
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications
Wei Ting Wang, Jiang‐Jiang Qin, Sukesh Voruganti, Subhasree Ashok Nag, Jianwei Zhou, Ruiwen Zhang · 2015 · Medicinal Research Reviews
Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease
Antonio Herrera-Merchan, Lorena Arranz, Jose Manuel Ligos, Antonio de Molina-Iracheta, Orlando Domı́nguez, Susana González · 2012 · Nature Communications · Retracted
3′UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice
Kazuhiko Ikeda, Philip J. Mason, Monica Bessler · 2011 · Blood